ABSTRACT
PURPOSE: Argon laser trabeculoplasty (ALT) is commonly used in the treatment of open-angle glaucoma. Varying success rates in lowering intraocular pressure (IOP) and controlling glaucoma are reported in studies with follow-up periods from 1 to 5 years, and few reports are available with follow-up to 10 years. The authors retrospectively reviewed the efficacy of ALT in patients followed up to 10 years. METHODS: Ninety-three patients with open-angle glaucoma underwent 360 degrees ALT. Mean follow-up was 52 +/- 43 months (mean +/- standard deviation; range, 1-132 months). Successful treatment at the time of final follow-up was defined as a decrease in IOP of 3 mmHg or greater from pretreatment level, IOP of 19 mmHg or less, stable visual field, stable optic nerve, and no further laser or surgical intervention. RESULTS: The decrease in IOP was 8.9 +/- 5.4 mmHg at 1 year, 10.0 +/- 4.2 mmHg at 5 years, and 8.9 +/- 5.2 mmHg at 10 years. The probability of success at 1 year was 77%, at 5 years 49%, and at 10 years 32%. Failure was most common in the first year after treatment (23%), and thereafter failure occurred at a rate of 5% to 9% per year. The mean decrease in IOP for all 93 eyes at time of maximum follow-up was 6.1 +/- 7.1 mmHg. CONCLUSION: Argon laser trabeculoplasty is an effective means for reducing IOP in many patients followed for an extended time. However, up to one half of eyes within 5 years of ALT and two thirds of eyes within 10 years may require additional laser or surgical intervention for glaucoma control.
Subject(s)
Glaucoma, Open-Angle/surgery , Laser Therapy , Trabeculectomy , Aged , Aged, 80 and over , Chronic Disease , Female , Follow-Up Studies , Glaucoma, Open-Angle/physiopathology , Humans , Intraocular Pressure , Longitudinal Studies , Male , Middle Aged , Prognosis , Reoperation , Retrospective Studies , Visual Acuity , Visual FieldsABSTRACT
We studied the toxicity of single doses of intravitreally administered alpha-interferon in albino rabbits. Doses of 420,000, 210,000, 105,000, 52,500, and 26,250 units/0.1 cc showed no significant histologic changes by light microscopy or altered retinal function assessed by photopic and scotopic electroretinography.
Subject(s)
Interferon Type I/toxicity , Vitreous Body , Animals , Electroretinography , Inflammation/chemically induced , Injections , Interferon Type I/administration & dosage , Rabbits , Retina/drug effects , Vitreous Body/drug effectsABSTRACT
We compared corneal penetration of idoxuridine (IDU) to liposome-encapsulated IDU. Liposomes of phosphatidic acid, phosphatidyl choline, and alpha-tocopherol in a molar ratio 1:8:1 were prepared using the reverse phase evaporation method. New Zealand albino rabbits received either 0.1% solution of I125-labelled aqueous IDU or liposome-encapsulated IDU topically every 2 min for 6 min. Corneal, aqueous, and vitreous samples were assayed for I125 radioactivity at 15 min and at 1, 2, 3, and 6 h following drug application. Our results indicated that corneal penetration of liposomal IDU was significantly increased over the regular form of the drug for a time interval of 6 h.
